Quiniodochlor is a halogenated hydroxyquinoline derivative with potent amoebicidal, antibacterial, and antifungal properties. It is primarily used as an intestinal amoebicide for the treatment of acute and chronic intestinal amoebiasis (dysentery). Its mechanism involves chelation of ferric ions essential for protozoal enzyme systems, leading to inhibition of parasitic metabolism. In the Indian context, it remains a relevant, cost-effective option for specific parasitic infections, though its use has declined in favor of newer agents like metronidazole and tinidazole due to safety concerns with prolonged use.
Adult: 250 mg orally three times daily for 7-10 days. Maximum: 750 mg/day.
Note: Take after meals with a full glass of water to minimize GI upset. Do not crush or chew the tablet. Complete the full course even if symptoms improve. Stools may turn dark green or black, which is harmless.
Quiniodochlor exerts its antiprotozoal and antibacterial effects through multiple mechanisms. Its primary action is chelation of ferric ions (Fe3+), which are essential cofactors for several enzymes in the electron transport chain of parasites like Entamoeba histolytica. This disrupts mitochondrial respiration and energy production. It also exhibits direct protozoacidal and bactericidal effects by interfering with DNA synthesis and uncoupling oxidative phosphorylation.
Pregnancy: Category C: Risk cannot be ruled out. Animal studies show toxicity. Use only if potential benefit justifies potential fetal risk, especially neurotoxicity. Avoid in first trimester.
Driving: May cause dizziness, blurred vision (if neurotoxicity occurs). Patients should be cautioned about driving or operating machinery if such symptoms develop.
| Levothyroxine | Quiniodochlor's iodine content may interfere with thyroid hormone replacement therapy, altering requirements. | Moderate |
| Antacids containing Aluminum, Calcium, or Magnesium | May decrease absorption of Quiniodochlor. Administer at least 2 hours apart. | Moderate |
| Oral Anticoagulants (Warfarin) | Potential increased risk of bleeding due to possible protein binding displacement. Monitor INR. | Moderate |
| Other Neurotoxic drugs (e.g., Isoniazid, Metronidazole) | Increased risk of peripheral neuropathy or CNS toxicity. Avoid concomitant use. | High |
Same composition (Quiniodochlor (250mg)), different brands: